-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA approves Merck’s Keytruda plus Padcev for perioperative muscle-invasive bladder cancer

PUBT·07/10/2026 18:11:12
Listen to the news
FDA approves Merck’s Keytruda plus Padcev for perioperative muscle-invasive bladder cancer
  • FDA cleared Keytruda, Keytruda QLEX with Padcev for perioperative treatment of adults with muscle-invasive bladder cancer, regardless of cisplatin eligibility.
  • Approval was backed by Phase 3 KEYNOTE-B15 data in cisplatin-eligible patients, showing event-free survival HR 0.53; overall survival HR 0.65.
  • Trial enrolled 808 patients; regimen is the first PD-1 inhibitor with an antibody-drug conjugate cleared in this setting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260710192353) on July 10, 2026, and is solely responsible for the information contained therein.